MLchartDataset catalogue

everolimus

Term · Oncology and biomedicine · MLC-T-ONC-003037

  1. A drug used alone or with other drugs to treat certain types of breast cancer, kidney cancer, and pancreatic, lung, and gastrointestinal neuroendocrine tumors. It is used under the brand name Afinitor to treat these cancers and to treat a type of benign kidney tumor called renal angiomyolipoma and a type of benign brain tumor called subependymal giant cell astrocytoma in patients who have tuberous sclerosis. Everolimus is also used under the brand name Afinitor Disperz to treat subependymal giant cell astrocytoma and certain types of seizures in patients who have tuberous sclerosis. It is also used under the brand name Zortress to keep the body from rejecting a kidney or liver transplant. Everolimus is also being studied in the treatment of other conditions and types of cancer. It blocks a protein involved in cell division, which may help keep abnormal cells, including cancer cells, from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Everolimus also lowers the body’s immune response. It is a type of kinase inhibitor, a type of angiogenesis inhibitor, and a type of immunosuppressant. Also called RAD001.

  2. A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production.

Table 1. Record
IdentifierMLC-T-ONC-003037
FieldOncology and biomedicine
SynonymsRAD001; 42-O-(2-hydroxy)ethyl rapamycin
ReferencesNCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-003037",
  "term": "everolimus",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used alone or with other drugs to treat certain types of breast cancer, kidney cancer, and pancreatic, lung, and gastrointestinal neuroendocrine tumors. It is used under the brand name Afinitor to treat these cancers and to treat a type of benign kidney tumor called renal angiomyolipoma and a type of benign brain tumor called subependymal giant cell astrocytoma in patients who have tuberous sclerosis. Everolimus is also used under the brand name Afinitor Disperz to treat subependymal giant cell astrocytoma and certain types of seizures in patients who have tuberous sclerosis. It is also used under the brand name Zortress to keep the body from rejecting a kidney or liver transplant. Everolimus is also being studied in the treatment of other conditions and types of cancer. It blocks a protein involved in cell division, which may help keep abnormal cells, including cancer cells, from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Everolimus also lowers the body’s immune response. It is a type of kinase inhibitor, a type of angiogenesis inhibitor, and a type of immunosuppressant. Also called RAD001.",
    "A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production."
  ],
  "synonyms": [
    "RAD001",
    "42-O-(2-hydroxy)ethyl rapamycin"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/everolimus/"
}

Record 6,999 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.